Product Description
please call me , to know more
AI Product Description
*The following content is generated by AI and is for reference only.
Bremelanotide, chemically known as PT-141, is a synthetic peptide derivative designed to mimic the action of alpha-melanocyte-stimulating hormone (α-MSH). Its molecular formula is C56H83N17O9S2, and it carries the CAS Registry Number 172979-06-3. Structurally, this compound consists of an octapeptide backbone where specific amino acid substitutions enhance its stability and potency compared to natural melanocortins. Unlike many other peptides in its class, Bremelanotide exhibits high selectivity for the MC4 receptor within the central nervous system while showing minimal affinity for the MC1 receptor, which is primarily responsible for skin pigmentation changes.
The primary clinical application of Bremelanotide is the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Marketed under the brand name Vyleesi, it was approved by the U.S. Food and Drug Administration in 2019 as a non-hormonal, on-demand therapy. The drug functions by activating the melanocortin pathway in the brain, specifically targeting areas involved in sexual arousal and motivation. Patients typically self-administer the medication via subcutaneous injection into the thigh or abdomen approximately 45 minutes before anticipated sexual activity. This mechanism distinguishes it from oral phosphodiesterase type 5 inhibitors, which are often used for erectile dysfunction but do not directly address low libido in women.
While effective for its intended indication, Bremelanotide usage requires careful medical supervision due to potential side effects. Common adverse reactions include nausea, flushing, headache, and increased blood pressure. Consequently, it is contraindicated for patients with uncontrolled hypertension or cardiovascular disease. Furthermore, because of its interaction with melanocortin receptors, there is a risk of transient hyperpigmentation, particularly in individuals with darker skin tones, although this effect is usually reversible upon discontinuation. Ongoing research continues to explore its potential therapeutic applications beyond sexual health, including its role in managing obesity and metabolic disorders through appetite regulation pathways. As a novel agent in the field of neuroendocrinology, Bremelanotide represents a significant advancement in addressing complex sexual dysfunctions that have historically lacked targeted pharmacological solutions.